Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanomaPaolo A. Ascierto, Antoni Ribas, Michal Lotem et al.|Nature Medicine|2019Cited by 328
Pembrolizumab plus lenalidomide and dexamethasone for patients with treatment-naive multiple myeloma (KEYNOTE-185): a randomised, open-label, phase 3 trialYukio Kondo, Fredrik Schjesvold, Albert Oriol et al.|The Lancet Haematology|2019Cited by 247
KEYNOTE-022 part 3: a randomized, double-blind, phase 2 study of pembrolizumab, dabrafenib, and trametinib in <i>BRAF</i>-mutant melanomaPier Francesco Ferrucci, Paolo A. Ascierto, Anna Maria Di Giacomo et al.|Journal for ImmunoTherapy of Cancer|2020Cited by 178
KEYNOTE-022 Part 3: Phase II randomized study of 1L dabrafenib (D) and trametinib (T) plus pembrolizumab (Pembro) or placebo (PBO) for BRAF-mutant advanced melanomaPaolo A. Ascierto, Antoni Ribas, Pier Francesco Ferrucci et al.|Annals of Oncology|2018Cited by 50
KEYNOTE-022: Pembrolizumab with trametinib in patients with BRAF wild-type melanoma or advanced solid tumours irrespective of BRAF mutationMichele Maio, Omid Hamid, Matteo S. Carlino et al.|European Journal of Cancer|2021Cited by 10